Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess the Efficacy of Erlotinib for Leptomeningeal Carcinomatosis in EGFR Mutation Positive Non-small Cell Lung Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Age \>18~2. Histologically or pathologically proven non-small cell lung cancer (NSCLC)~3. Leptomeningeal carcinomatosis confirmed by CSF cytology~4. A patients with EGFR mutation (including exon 19 deletion, L858R)~5. ECOG performance status 0-3~6. Expected life time more than at least 4 weeks~7. A patients who signed the informed consent prior to the participation in the study~8. Chemotherapy-naïve patient is eligible~9. Previous EGFR TKI is allowed if this drug was not specifically used for CNS metastases~Exclusion Criteria:~1. A pregnant or lactating patient~2. A patient of childbearing potential without being tested for pregnancy at baseline or with a positive test. (A postmenopausal woman with the amenorrhea period of at least 12 months or longer is considered to have non-childbearing potential.)~3. A man or woman of childbearing potential without the willingness to use a contraceptive measures during the study~4. A patient with history of another malignant disease within past 3 years, except curatively treated basal cell carcinoma of the skin, cervical carcinoma in situ, and early gastric cancer~5. A patient with active interstitial lung disease, except simple lymphangitic lung metastasis~6. A patient with history of allergic reaction to gefitinib or erlotinib~7. The following laboratory test results:~   * Number of absolute neutrophils counts (ANC) \< 1.0ⅹ109/L~  * Number of platelets \< 50 ⅹ109/L~  * AST, ALT \> 2.5 ⅹupper limit of normal~  * Total bilirubin \> 1.5 ⅹupper limit of normal~  * Serum creatinine \> 1.5 ⅹupper limit of normal~8. A patient with serious disease as followings~   * Uncontrolled cardiac arrhythmia~  * History of myocardial infarction within 6 months prior to the initiation of study~  * Neurological or psychiatric disorder including dementia or uncontrolled seizure~9. A patient who refused to sign the informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Erlotinib (Type: EXPERIMENTAL): Erlotinib 150mg/day (if no negative conversion --\> increment to 250mg/day)

Based on this trial design, predict the completion outcome and termination type (if applicable).